These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 1948125)

  • 41. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
    Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
    N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.
    Salmon SE; Haut A; Bonnet JD; Amare M; Weick JK; Durie BG; Dixon DO
    J Clin Oncol; 1983 Aug; 1(8):453-61. PubMed ID: 6366141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.
    Bell JB; Barfoot R; Iveson T; Powles RL; Millar BC
    Br J Cancer; 1994 Oct; 70(4):646-51. PubMed ID: 7917911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-alpha in the treatment of multiple myeloma.
    Khoo TL; Vangsted AJ; Joshua D; Gibson J
    Curr Drug Targets; 2011 Mar; 12(3):437-46. PubMed ID: 21143148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of myeloma.
    Smith ML; Newland AC
    QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
    Boccadoro M; Avvisati G; Cantonetti M; Cavo-Comotti BM; Frieri R; Gallamini A; Gallone G; Lauta VM; Liberati M; Marmont F
    Pathol Biol (Paris); 1990 Oct; 38(8):829. PubMed ID: 2274374
    [No Abstract]   [Full Text] [Related]  

  • 49. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
    Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model.
    Manning LS; Chamberlain NL; Leahy MF; Cordingley FT
    Immunol Cell Biol; 1995 Aug; 73(4):326-32. PubMed ID: 7493769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatments of multiple myeloma in 1992].
    Monconduit M
    Rev Med Interne; 1992; 13(4):315-8. PubMed ID: 1363152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The polychemotherapy of patients with multiple myeloma].
    Abdulkadyrov KM; Bessmel'tsev SS
    Vopr Onkol; 1992; 38(3):345-51. PubMed ID: 1300725
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of multiple myeloma with interferon alpha: the Scandinavian experience.
    Mellstedt H; Osterborg A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Juliusson G
    Br J Haematol; 1991 Oct; 79 Suppl 1():21-5. PubMed ID: 1931703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic strategies and controversies in the treatment of multiple myeloma.
    Bladé J
    Pathol Biol (Paris); 1999 Feb; 47(2):192-8. PubMed ID: 10192888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
    Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
    Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of alpha-interferon in multiple myeloma.
    Peest D
    Pathol Biol (Paris); 1999 Feb; 47(2):172-7. PubMed ID: 10192884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.